Home-Time After Discharge Among Patients Hospitalized With Heart Failure

Journal of the American College of Cardiology

Volumn 71, Issue 23, 2018, Pages 2643-2652

  Greene, Stephen J ^a,b   O'Brien, Emily C ^a,b   Mentz, Robert J ^a,b   Luo, Nancy ^a,b   Hardy, N Chantelle ^b   Laskey, Warren K ^c   Heidenreich, Paul A ^d   Chang, Chun Lan ^e   Turner, Stuart J ^e   Yancy, Clyde W ^f   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^a,b   Peterson, Pamela N ^g,h   Fonarow, Gregg C ⁱ   Hammill, Bradley G ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h DENVER HEALTH MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

heart failure; hospitalization; outcomes; patient centered; post discharge

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DEMENTIA; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEART FAILURE; HOME TIME; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; TIME; COHORT ANALYSIS; MORTALITY; PROSPECTIVE STUDY; SELF CARE; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PATIENT DISCHARGE; PROSPECTIVE STUDIES; REGISTRIES; SELF CARE;

EID: 85047513936     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.03.517     Document Type: Article

References (38)

1. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
2. Blecker, S., Paul, M., Taksler, G., Ogedegbe, G., Katz, S., Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 61 (2013), 1259–1267.
3. Krumholz, H.M., Normand, S.L., Wang, Y., Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999–2011. Circulation 130 (2014), 966–975.
4. Allen, L.A., Gheorghiade, M., Reid, K.J., et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 4 (2011), 389–398.
5. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
6. Institute of Medicine Committee on Quality of Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century, 2001, National Academy Press, Washington, DC.
7. Allen, L.A., Yager, J.E., Funk, M.J., et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 299 (2008), 2533–2542.
8. Hernandez, A.F., Fleurence, R.L., Rothman, R.L., The ADAPTABLE trial and PCORnet: shining light on a new research paradigm. Ann Intern Med 163 (2015), 635–636.
9. Jones, W.S., Roe, M.T., Antman, E.M., et al. The changing landscape of randomized clinical trials in cardiovascular disease. J Am Coll Cardiol 68 (2016), 1898–1907.
10. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed July 26, 2017.
11. Fonarow, G.C., Liang, L., Thomas, L., et al. Assessment of home-time after acute ischemic stroke in Medicare beneficiaries. Stroke 47 (2016), 836–842.
12. O'Brien, E.C., Xian, Y., Xu, H., et al. Hospital variation in home-time after acute ischemic stroke: insights from the PROSPER Study (Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research). Stroke 47 (2016), 2627–2633.
13. Smaha, L.A., American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J 148 (2004), S46–S48.
14. Hong, Y., LaBresh, K.A., Overview of the American Heart Association “Get with the Guidelines” programs: coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol 5 (2006), 179–186.
15. Hammill, B.G., Hernandez, A.F., Peterson, E.D., Fonarow, G.C., Schulman, K.A., Curtis, L.H., Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 157 (2009), 995–1000.
16. Krumholz, H.M., Wang, Y., Mattera, J.A., et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 113 (2006), 1693–1701.
17. Wasywich, C.A., Gamble, G.D., Whalley, G.A., Doughty, R.N., Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of ‘days alive and out of hospital’ from epidemiological data. Eur J Heart Fail 12 (2010), 462–468.
18. Hauptman, P.J., Goodlin, S.J., Lopatin, M., Costanzo, M.R., Fonarow, G.C., Yancy, C.W., Characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care. Arch Intern Med 167 (2007), 1990–1997.
19. Allen, L.A., Hernandez, A.F., Peterson, E.D., et al. Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail 4 (2011), 293–300.
20. Gheorghiade, M., Ruschitzka, F., Beyond dyspnoea as an endpoint in acute heart failure trials. Eur Heart J 32 (2011), 1442–1445.
21. Mebazaa, A., Pang, P.S., Tavares, M., et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 31 (2010), 832–841.
22. Estep, J.D., Starling, R.C., Horstmanshof, D.A., et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 66 (2015), 1747–1761.
23. Vaduganathan, M., Bonow, R.O., Gheorghiade, M., Thirty-day readmissions: the clock is ticking. JAMA 309 (2013), 345–346.
24. Joynt, K.E., Jha, A.K., Thirty-day readmissions–truth and consequences. N Engl J Med 366 (2012), 1366–1369.
25. Pandey, A., Golwala, H., Xu, H., et al. Association of 30-day readmission metric for heart failure under the Hospital Readmissions Reduction Program with quality of care and outcomes. J Am Coll Cardiol HF 4 (2016), 935–946.
26. Kociol, R.D., Liang, L., Hernandez, A.F., et al. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J 165 (2013), 987–994.e1.
27. Vaduganathan, M., Greene, S.J., Ambrosy, A.P., Gheorghiade, M., Butler, J., The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10 (2013), 85–97.
28. Ambrosy, A.P., Butler, J., Gheorghiade, M., Clinical trials in acute heart failure: beginning of the end or end of the beginning?. Eur J Heart Fail 19 (2017), 1358–1360.
29. Greene, S.J., Gheorghiade, M., Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 64 (2014), 1599–1601.
30. Greene, S.J., Gheorghiade, M., Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. Eur J Heart Fail 17 (2015), 875–878.
31. Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
32. O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
33. Gheorghiade, M., Bohm, M., Greene, S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309 (2013), 1125–1135.
34. Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
35. Packer, M., Development and evolution of a hierarchical clinical composite end point for the evaluation of drugs and devices for acute and chronic heart failure: a 20-year perspective. Circulation 134 (2016), 1664–1678.
36. Felker, G.M., Maisel, A.S., A global rank end point for clinical trials in acute heart failure. Circ Heart Fail 3 (2010), 643–646.
37. Hawkins, N.M., Jhund, P.S., McMurray, J.J., Capewell, S., Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail 14 (2012), 138–146.
38. Akintoye, E., Briasoulis, A., Egbe, A., et al. Regional variation in mortality, length of stay, cost, and discharge disposition among patients admitted for heart failure in the United States. Am J Cardiol 120 (2017), 817–824.